Jinseok Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jinseok Kim has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Eun-Jung Park
Division of Rheumatology, Department of Internal Medicine, National Medical Center, Seoul, Korea
6 shared publicationsByeongzu Ghang
Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea
4 shared publications- Byeongzu Ghang
Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea
4 shared publications Changlim Hyun
Department of Pathology, Jeju National University Hospital, Jeju, Republic of Korea
3 shared publicationsChangmin Choi
Department of Medicine, Jeju National University School of Medicine, Jeju, Republic of Korea
3 shared publicationsHyunwoo Kim
Division of Nephrology, Department of Internal Medicine, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Korea
3 shared publications
Latest Publications
- Open Access
- 30 May 2025
- Published by Jeju National University Institute for Medical Science in Journal of Medicine and Life Science
- Vol. 22 (2) , 53-59
The effect of uric acid-lowering therapy on vascular stiffness in patients with gout
Several studies have reported that vascular stiffness and risk of cardiovascular disease increase in patients with gout. Although it has been reported that uric acid-lowering treatment improves vascular stiffness in several patient groups, it remains unclear whether uric acid-lowering treatment improves vascular stiffness in patients with gout. Therefore, this study aimed to determine whether vascular stiffness improves by measuring the augmentation index along with uric acid-lowering treatment for 2 years in patients with gout. This study showed that vascular stiffness improved in 67% of the patients, and patients with high initial vascular stiffness showed better improvement in vascular stiffness after uric acid-lowering treatment. Regression analysis was performed to identify factors that improved vascular stiffness; however, no factors that improved vascular stiffness were found. Among patients who had already received uric acid-lowering treatment for more than 2 years before starting augmentation index measurements, 67.7% showed improvement in vascular stiffness. Therefore, it is believed that uric acid-lowering treatment in patients with gout can improve vascular stiffness, and if uric acid-lowering treatment is continued, improvement in vascular stiffness is expected to occur gradually over a long period of time.
- 30 May 2025
- Published by Jeju National University Institute for Medical Science in Journal of Medicine and Life Science
- Vol. 22 (2) , 53-59
Open AccessThe effect of uric acid-lowering therapy on vascular stiffness in patients with gout
Several studies have reported that vascular stiffness and risk of cardiovascular disease increase in patients with gout. Although it has been reported that uric acid-lowering treatment improves vascular stiffness in several patient groups, it remains unclear whether uric acid-lowering treatment improves vascular stiffness in patients with gout. Therefore, this study aimed to determine whether vascular stiffness improves by measuring the augmentation index along with uric acid-lowering treatment for 2 years in patients with gout. This study showed that vascular stiffness improved in 67% of the patients, and patients with high initial vascular stiffness showed better improvement in vascular stiffness after uric acid-lowering treatment. Regression analysis was performed to identify factors that improved vascular stiffness; however, no factors that improved vascular stiffness were found. Among patients who had already received uric acid-lowering treatment for more than 2 years before starting augmentation index measurements, 67.7% showed improvement in vascular stiffness. Therefore, it is believed that uric acid-lowering treatment in patients with gout can improve vascular stiffness, and if uric acid-lowering treatment is continued, improvement in vascular stiffness is expected to occur gradually over a long period of time.
- Open Access
- 28 February 2025
- Published by Korean Society of Biological Nursing Science in Journal of Korean Biological Nursing Science
- Vol. 27 (1) , 126-132
Relationship between lower urinary tract symptoms and disease activity among women with systemic lupus erythematosus in Korea: a cross-sectional study
Purpose: Bladder involvement in the disease course of systemic lupus erythematosus (SLE) is uncommon; in fact, it has been shown that patients with SLE have lower urinary tract symptoms (LUTS) than the general population. This study aimed to identify LUTS and the relationship between LUTS and disease activity among women with SLE.Methods: This cross-sectional study used structured self-administered questionnaires. We recruited 110 women with SLE from the outpatient clinic of a university hospital between January and August of 2020. LUTS was assessed using the International Prostate Symptom Score, and disease activity was assessed using the Systemic Lupus Activity Questionnaire.Results: Fifty-seven women (51.8%) reported urinary incontinence (UI), while 53 (48.2%) reported no UI. The mean LUTS score was 7.75 ± 5.74 (range 0-35). The scores for the seven LUTS components (range 0-5) were as follows: frequency (1.51 ± 1.48), nocturia (1.46 ± 1.07), urgency (1.27 ± 1.35), incomplete emptying (1.09 ± 1.15), intermittency (0.97 ± 1.27), weak stream (0.94 ± 1.04), and straining (0.51 ± 0.91). LUTS were positively correlated with the disease activity of SLE (r = .48, p < .001), indicating that higher LUTS scores were associated with severe disease activity.Conclusion: The prevalence of UI was high, and LUTS (frequency, nocturia, and urgency) were common. Therefore, regular assessment and appropriate management of UI and LUTS among women with SLE are necessary, and it is also essential to keep the disease activity of SLE at a low level due to the positive relationship between disease activity and LUTS.
- 28 February 2025
- Published by Korean Society of Biological Nursing Science in Journal of Korean Biological Nursing Science
- Vol. 27 (1) , 126-132
Open AccessRelationship between lower urinary tract symptoms and disease activity among women with systemic lupus erythematosus in Korea: a cross-sectional study
Purpose: Bladder involvement in the disease course of systemic lupus erythematosus (SLE) is uncommon; in fact, it has been shown that patients with SLE have lower urinary tract symptoms (LUTS) than the general population. This study aimed to identify LUTS and the relationship between LUTS and disease activity among women with SLE.Methods: This cross-sectional study used structured self-administered questionnaires. We recruited 110 women with SLE from the outpatient clinic of a university hospital between January and August of 2020. LUTS was assessed using the International Prostate Symptom Score, and disease activity was assessed using the Systemic Lupus Activity Questionnaire.Results: Fifty-seven women (51.8%) reported urinary incontinence (UI), while 53 (48.2%) reported no UI. The mean LUTS score was 7.75 ± 5.74 (range 0-35). The scores for the seven LUTS components (range 0-5) were as follows: frequency (1.51 ± 1.48), nocturia (1.46 ± 1.07), urgency (1.27 ± 1.35), incomplete emptying (1.09 ± 1.15), intermittency (0.97 ± 1.27), weak stream (0.94 ± 1.04), and straining (0.51 ± 0.91). LUTS were positively correlated with the disease activity of SLE (r = .48, p < .001), indicating that higher LUTS scores were associated with severe disease activity.Conclusion: The prevalence of UI was high, and LUTS (frequency, nocturia, and urgency) were common. Therefore, regular assessment and appropriate management of UI and LUTS among women with SLE are necessary, and it is also essential to keep the disease activity of SLE at a low level due to the positive relationship between disease activity and LUTS.
- 15 November 2024
- Published by Elsevier in Kidney International
- Vol. 107 (3) , 521-529
Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy
- 15 November 2024
- Published by Elsevier in Kidney International
- Vol. 107 (3) , 521-529
Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy
- Open Access
- 8 June 2023
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 30 (3) , 185-197
Regional variations of cardiovascular risk in gout patients: a nationwide cohort study in Korea
Hyun Jung Kim, Ph.D., Byeongzu Ghang, M.D., Ph.D., Jinseok Kim, M.D., Ph.D., Hyeong Sik Ahn, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2023.0011
- 8 June 2023
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 30 (3) , 185-197
Open AccessRegional variations of cardiovascular risk in gout patients: a nationwide cohort study in Korea
Hyun Jung Kim, Ph.D., Byeongzu Ghang, M.D., Ph.D., Jinseok Kim, M.D., Ph.D., Hyeong Sik Ahn, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2023.0011
- 2 September 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (12) , 5618-5620
Autoimmune rheumatic disease after SARS‐CoV‐2 vaccination
- 2 September 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (12) , 5618-5620
Autoimmune rheumatic disease after SARS‐CoV‐2 vaccination
- Open Access
- 5 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (31) , e29960
The combination of osteoporosis and low lean mass correlates with physical function in end-stage knee osteoarthritis: A retrospective observational study
We aimed to investigate the prevalence of osteoporosis and low lean mass, either together or in isolation, and their association with physical function, pain, and quality of life (QOL) in patients with end-stage knee osteoarthritis (OA). This retrospective cross-sectional observational study included 578 patients (77 males and 501 females) diagnosed with end-stage knee OA. Patients were divided into 4 groups based on body composition parameters: control, osteoporosis, low lean mass, and osteoporosis + low lean mass. All participants underwent performance-based physical function tests, including a stair climbing test (SCT), a 6-minute walk test, a timed up and go test, and instrumental gait analysis, to examine spatiotemporal parameters. Self-reported physical function and pain levels were measured using the Western Ontario McMaster Universities Osteoarthritis Index and visual analog scale, respectively. Self-reported QOL was measured using the EuroQOL 5 dimensions (EQ-5D) questionnaire. Of 578 patients, 268 (46.4%) were included in the control group, 148 (25.6%) in the osteoporosis group, 106 (18.3%) in the low lean mass group, and 56 (9.7%) in the osteoporosis + low lean mass group. Analysis of variance revealed that the scores for the osteoporosis + low lean mass group in the SCT-ascent, SCT-descent, and timed up and go test were significantly higher, whereas those for the 6-minute walk test, gait speed, and cadence were significantly lower than those for the other groups (P < .05). After adjusting for age, sex, and body mass index, multiple linear regression analysis identified SCT-ascent (β = 0.140, P = .001, R 2 = 0.126), SCT-descent (β = 0.182, P < .001, R 2 = 0.124), gait speed (β = –0.116, P = .005, R 2 = 0.079), and cadence (β = –0.093, P = .026, R 2 = 0.031) as being significantly associated with osteoporosis + low lean mass. Thus, osteoporosis + low lean mass correlates with poor physical function, but not pain and QOL, in patients with end-stage knee OA.
- 5 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (31) , e29960
Open AccessThe combination of osteoporosis and low lean mass correlates with physical function in end-stage knee osteoarthritis: A retrospective observational study
We aimed to investigate the prevalence of osteoporosis and low lean mass, either together or in isolation, and their association with physical function, pain, and quality of life (QOL) in patients with end-stage knee osteoarthritis (OA). This retrospective cross-sectional observational study included 578 patients (77 males and 501 females) diagnosed with end-stage knee OA. Patients were divided into 4 groups based on body composition parameters: control, osteoporosis, low lean mass, and osteoporosis + low lean mass. All participants underwent performance-based physical function tests, including a stair climbing test (SCT), a 6-minute walk test, a timed up and go test, and instrumental gait analysis, to examine spatiotemporal parameters. Self-reported physical function and pain levels were measured using the Western Ontario McMaster Universities Osteoarthritis Index and visual analog scale, respectively. Self-reported QOL was measured using the EuroQOL 5 dimensions (EQ-5D) questionnaire. Of 578 patients, 268 (46.4%) were included in the control group, 148 (25.6%) in the osteoporosis group, 106 (18.3%) in the low lean mass group, and 56 (9.7%) in the osteoporosis + low lean mass group. Analysis of variance revealed that the scores for the osteoporosis + low lean mass group in the SCT-ascent, SCT-descent, and timed up and go test were significantly higher, whereas those for the 6-minute walk test, gait speed, and cadence were significantly lower than those for the other groups (P < .05). After adjusting for age, sex, and body mass index, multiple linear regression analysis identified SCT-ascent (β = 0.140, P = .001, R 2 = 0.126), SCT-descent (β = 0.182, P < .001, R 2 = 0.124), gait speed (β = –0.116, P = .005, R 2 = 0.079), and cadence (β = –0.093, P = .026, R 2 = 0.031) as being significantly associated with osteoporosis + low lean mass. Thus, osteoporosis + low lean mass correlates with poor physical function, but not pain and QOL, in patients with end-stage knee OA.
- Open Access
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
Objectives The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after discontinuation of febuxostat or allopurinol. We investigated whether major adverse cardiovascular events (MACE) and CV death were increased because of discontinuation of febuxostat or allopurinol using the CARES trial data. Methods We compared the MACE that occurred during administration and after discontinuation in the initial phase after discontinuation, and we compared the CV and non-CV mortality rates in the initial phase after discontinuation to determine the impact of discontinuation of febuxostat or allopurinol. Results Among 6190 patients, the incidence rate per 100 person-years for MACE was 3.11 during administration and 6.71 after discontinuation. MACE was significantly increased after discontinuation compared with that during administration within 1 month (HR 7.40; 95% CI 5.38 to 10.17) and 6 months (HR 5.22; 95% CI 4.26 to 6.39). In the analysis excluding death induced by adverse events that occurred up to 1 day after the last medication, the CV mortality rate was higher than the non-CV mortality rate within 6 months (45.7% vs 27.9%, p=0.0001). In addition, changes in serum uric acid levels from baseline to the last measurement before discontinuation were significantly associated with higher MACE risk after drug discontinuation (HR 1.14; 95% CI 1.04 to 1.26). Conclusions MACE and CV death were increased in the initial stage after discontinuation of febuxostat or allopurinol in patients with gout.
Open AccessIncreased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
Objectives The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after discontinuation of febuxostat or allopurinol. We investigated whether major adverse cardiovascular events (MACE) and CV death were increased because of discontinuation of febuxostat or allopurinol using the CARES trial data. Methods We compared the MACE that occurred during administration and after discontinuation in the initial phase after discontinuation, and we compared the CV and non-CV mortality rates in the initial phase after discontinuation to determine the impact of discontinuation of febuxostat or allopurinol. Results Among 6190 patients, the incidence rate per 100 person-years for MACE was 3.11 during administration and 6.71 after discontinuation. MACE was significantly increased after discontinuation compared with that during administration within 1 month (HR 7.40; 95% CI 5.38 to 10.17) and 6 months (HR 5.22; 95% CI 4.26 to 6.39). In the analysis excluding death induced by adverse events that occurred up to 1 day after the last medication, the CV mortality rate was higher than the non-CV mortality rate within 6 months (45.7% vs 27.9%, p=0.0001). In addition, changes in serum uric acid levels from baseline to the last measurement before discontinuation were significantly associated with higher MACE risk after drug discontinuation (HR 1.14; 95% CI 1.04 to 1.26). Conclusions MACE and CV death were increased in the initial stage after discontinuation of febuxostat or allopurinol in patients with gout.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (46) , e329
Balloon Angioplasty for Hyperaldosteronism in Renal Artery Stenosis due to Takayasu Arteritis
Jeong W, et al. J Korean Med Sci. 2022 Nov;37(46):e329. https://doi.org/10.3346/jkms.2022.37.e329
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (46) , e329
Open AccessBalloon Angioplasty for Hyperaldosteronism in Renal Artery Stenosis due to Takayasu Arteritis
Jeong W, et al. J Korean Med Sci. 2022 Nov;37(46):e329. https://doi.org/10.3346/jkms.2022.37.e329
- Open Access
- 1 January 2022
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 29 (1) , 56-57
Colchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine
Byeongzu Ghang, M.D., Jinseok Kim, M.D.. J Rheum Dis 2022;29:56-7. https://doi.org/10.4078/jrd.2022.29.1.56
- 1 January 2022
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 29 (1) , 56-57
Open AccessColchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine
Byeongzu Ghang, M.D., Jinseok Kim, M.D.. J Rheum Dis 2022;29:56-7. https://doi.org/10.4078/jrd.2022.29.1.56
- Open Access
- 5 March 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (3) , 184
Prognostic Factors for Radiographic Progression in Patients with Seronegative Rheumatoid Arthritis
(1) Background: It has long been suggested that seronegative rheumatoid arthritis (RA) represents a clinical entity quite distinct from that of seropositive. However, analytical studies of seronegative RA dedicated to clinical outcomes regarding radiographic progression and related risk factors are scarce. The aim of this study is to evaluate radiographic outcome and prognostic factors for radiographic progression in patients with seronegative rheumatoid arthritis. (2) Methods: Subjects included RA patients reported as seronegative for both rheumatoid factor and anti-citrullinated protein antibody, who were treated at Jeju National University Hospital in South Korea between 2003 and 2016, including follow-up of at least 2 years. All patients fulfilled 1987 ACA or 2010 ACR/EULAR RA criteria. Radiographic progression was measured by yearly change in the Sharp van der Heijde (SvdH) score during follow-up periods. Medical records, laboratory and radiographic data were retrospectively analyzed, and linear regression analysis was performed to evaluate prognostic factors for radiographic progression in patients with seronegative rheumatoid arthritis. (3) Results: In total, 116 patients with seronegative RA were observed and 43 (37.1%) patients demonstrated radiographic damage during follow-up period. Mean age at diagnosis was 48 years and 86 (74.1%) patients were female. Symptom duration at diagnosis was 1.3 years and mean follow-up duration was 5.2 years. Patients with radiographic damage at diagnosis were 14 (12.1%) and mean SvdH score was 6.8 at diagnosis. Radiographic damage and SvdH at diagnosis significantly correlated with radiographic progression in patients with seronegative RA after adjusting age, sex, symptom duration, number of active synovitis, and CRP at diagnosis (β-coefficient 6.5 ± 1.84; p = 0.001 and β-coefficient 0.12 ± 0.02; p < 0.001, respectively). (4) Conclusions: This study determined that radiographic damage and SvdH at diagnosis were predictive factors in progression of radiographic damage in patients with seronegative rheumatoid arthritis. A large comparative study dedicated to this issue in seronegative RA is required.
- 5 March 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (3) , 184
Open AccessPrognostic Factors for Radiographic Progression in Patients with Seronegative Rheumatoid Arthritis
(1) Background: It has long been suggested that seronegative rheumatoid arthritis (RA) represents a clinical entity quite distinct from that of seropositive. However, analytical studies of seronegative RA dedicated to clinical outcomes regarding radiographic progression and related risk factors are scarce. The aim of this study is to evaluate radiographic outcome and prognostic factors for radiographic progression in patients with seronegative rheumatoid arthritis. (2) Methods: Subjects included RA patients reported as seronegative for both rheumatoid factor and anti-citrullinated protein antibody, who were treated at Jeju National University Hospital in South Korea between 2003 and 2016, including follow-up of at least 2 years. All patients fulfilled 1987 ACA or 2010 ACR/EULAR RA criteria. Radiographic progression was measured by yearly change in the Sharp van der Heijde (SvdH) score during follow-up periods. Medical records, laboratory and radiographic data were retrospectively analyzed, and linear regression analysis was performed to evaluate prognostic factors for radiographic progression in patients with seronegative rheumatoid arthritis. (3) Results: In total, 116 patients with seronegative RA were observed and 43 (37.1%) patients demonstrated radiographic damage during follow-up period. Mean age at diagnosis was 48 years and 86 (74.1%) patients were female. Symptom duration at diagnosis was 1.3 years and mean follow-up duration was 5.2 years. Patients with radiographic damage at diagnosis were 14 (12.1%) and mean SvdH score was 6.8 at diagnosis. Radiographic damage and SvdH at diagnosis significantly correlated with radiographic progression in patients with seronegative RA after adjusting age, sex, symptom duration, number of active synovitis, and CRP at diagnosis (β-coefficient 6.5 ± 1.84; p = 0.001 and β-coefficient 0.12 ± 0.02; p < 0.001, respectively). (4) Conclusions: This study determined that radiographic damage and SvdH at diagnosis were predictive factors in progression of radiographic damage in patients with seronegative rheumatoid arthritis. A large comparative study dedicated to this issue in seronegative RA is required.